Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant ...
Hosted on MSN1y
New COVID-19 sub-variant 'Arcturus' detected in at least 24 countries; Here's all you need to know about itWATCH | Russia using facial recognition to crack down on youngsters dodging compulsory military service Experts are examining the Arcturus sub-variant closely. However, they are not concerned ...
The latest price target for Arcturus Therapeutics (NASDAQ:ARCT) was reported by Canaccord Genuity on March 10, 2025. The analyst firm set a price target for $68.00 expecting ARCT to rise to within ...
Explore Arcturus Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for ARCT. Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer ...
SAN DIEGO, March 06, 2025--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development ...
SAN DIEGO, March 05, 2025--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development ...
Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including mRNA, siRNA, replicon RNA, asRNA, DNA, and gene editing therapeutics.
Arcturus Therapeutics Holdings Inc. (ARCT) reported a wider-than-expected loss for the fourth quarter of 2024, with earnings per share (EPS) of -$1.11, missing the forecast of -$0.19. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback